Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KSQ 004 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 09 Apr 2025 According to KSQ Therapeutics media release, company announced that the first patient has been dosed in the Phase 1/2 clinical study of KSQ-004EX. The first patient treated with KSQ-004EX was enrolled by Rodabe Amaria, M.D., professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • 26 Nov 2024 Status changed from not yet recruiting to recruiting.
  • 25 Sep 2024 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top